Hong Kong-listed biotech firm Innovent Biologics (1801.HK) saw its shares soar 5.17% in intraday trading on Friday, following news that its third-generation EGFR TKI drug Limertinib received approval from China's medical regulator NMPA for treatment of a certain mutation in non-small cell lung cancer.
Limertinib targets the EGFR T790M mutation, which is present in up to 50% of Asian lung cancer patients with locally advanced or metastatic non-small cell lung cancer. This regulatory milestone clears the way for Innovent to market the drug and potentially opens up a significant revenue stream for the biotech firm.
The approval boosts Innovent's oncology drug pipeline and is a major win as it seeks to expand its portfolio of marketed products beyond its existing PD-1 antibody Tyvyt. Investors cheered the development, betting that Limertinib can become a blockbuster therapy given the high prevalence of the targetted mutation in Asian patient populations.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。